Gexiang Cai
Wenzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Identifying prioritization of potential targets for idiopathic pulmonary fibrosis: Proteome-wide Mendelian randomization and colocalization analyses.
Journal: Clinics (Sao Paulo, Brazil)
Published: September 09, 2025
Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.
Journal: Lipids in health and disease
Published: May 08, 2024
Comparison of hypoxia-induced pulmonary hypertension rat models caused by different hypoxia protocols.
Journal: Experimental lung research
Published: November 24, 2022
Hypocrellin A exerts antitumor effects by inhibiting the FGFR1 signalling pathway in non-small cell lung cancer: Volume and pages of the publication: Phytomedicine 97 (2022) 153924.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: March 28, 2022
Hypocrellin A exerts antitumor effects by inhibiting the FGFR1 signaling pathway in non-small cell lung cancer.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: October 07, 2021
FGF21 attenuates hypoxia‑induced dysfunction and inflammation in HPAECs via the microRNA‑27b‑mediated PPARγ pathway.
Journal: International journal of molecular medicine
Published: November 13, 2020
Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension.
Journal: Experimental biology and medicine (Maywood, N.J.)
Published: February 05, 2019
Fibroblast growth factor 21 attenuates hypoxia-induced pulmonary hypertension by upregulating PPARγ expression and suppressing inflammatory cytokine levels.
Journal: Biochemical and biophysical research communications
Published: August 17, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026